

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2017 WB

DESPATCHED ON 31ST JANUARY 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A11, A24; B7, B18; Cw7, Cw-; DR11, DR15; DQ6, DQ7

					Summary of Results												
					PBL				T-Cells				B-Cells				
Total tested	11	9	10	11	21	17	21	20	21	22	22	21	21				
Positive	3	9	0	4	0	5	0	7	2	22	1	9	9				
Negative	8	0	10	7	21	12	21	13	19	0	21	12	12				
NT/Equivocal	0	2	1	0	0	4	0	1	1	0	0	1	1				
% Positive	27.3%	100.0%	0.0%	36.4%	0.0%	29.4%	0.0%	35.0%	9.5%	100.0%	4.5%	42.9%	42.9%				
% Negative	72.7%	0.0%	100.0%	63.6%	100.0%	70.6%	100.0%	65.0%	90.5%	0.0%	95.5%	57.1%	57.1%				
Consensus	Not Assessed	Positive	Negative	Not Assessed	Negative	Not Assessed	Negative	Not Assessed	Negative	Positive	Negative	Not Assessed	Not Assessed				
HLA Antibody Specificity (Defined By CDC)	A3	A10, B16, DQ1	B44, Cw5, DR4	?Bw6	A3	A10, B16, DQ1	B44, Cw5, DR4	?Bw6	A3	A10, B16, DQ1	B44, Cw5, DR4	?Bw6	?Bw6				
					Without DTT				Without DTT				Without DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment		Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
9	YES	YES	YES		Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	
11	YES	YES	YES		Negative	Positive	Equivocal	Positive	Negative	Negative	Negative	Positive	Equivocal	Positive	Positive	Positive	
12	YES	YES	YES		Negative	Equivocal	Negative	Negative	Negative	Equivocal	Negative	Negative	Negative	Positive	Negative	Negative	
14	YES	YES	YES		Negative	Positive	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	Positive	
20	YES	YES	YES		Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
23		YES	YES		Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	Positive	Poor quality B cells
24		YES	YES		Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	Positive	
25		YES	YES		Negative	Equivocal	Negative	Negative	Negative	Equivocal	Negative	Negative	Negative	Positive	Negative	Negative	
28		YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	
34		YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Positive	
35	YES	YES	YES		Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
38	YES	YES	YES		Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
39		YES	YES		Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
41		YES	YES		Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	
42	YES	YES	YES		Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
45		YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
51		YES	YES		Negative	Negative	Equivocal	Positive	Negative	Equivocal	Negative	Positive	Negative	Positive	Negative	Positive	
54		YES	YES		Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	Negative	
58		YES	YES		Negative	Positive	Negative	Equivocal	Negative	Equivocal	Negative	Equivocal	Negative	Positive	Negative	Equivocal	
117	YES				Positive	Equivocal	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	The bad viability of cells made the reading of the crossmatch difficult
136		YES			Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
149	YES				Positive	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
205	YES		YES		Positive	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
212	YES	YES	YES		Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
311		YES	YES		Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
315		YES	YES		Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A01/2017 WB

DESPATCHED ON 31ST JANUARY 2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	4	0	2	0	2	0	0	0	8	0	2	95	95	90
11	-	2	Equivocal	2	-	-	-	6	Equivocal	8	2	6	95	95	95
12	-	Equivocal	-	-	-	Equivocal	-	-	-	100%	-	-	90	90	90
14					0	0	0	2	0	8	0	8		90	90
20	10%	30%	10%	10%					10%	90%	10%	10%	90		90
23					1	1	1	4	1	8	1	8		90	60
24					20%	30%	10%	50%	30%	100%	30%	80%		90	80
25					1	Equivocal	1	1	1	8	1	1		85	80
28					1	1	1	1	1	8	1	4		99	90
34					1	1	1	1	2	8	1	2		99	90
35	1	2	1	4	1	2	1	8					70	60	
38	1	4	1	2	1	4	1	1	1	8	1	1	85	85	85
39					-	-	-	-	-	8	-	-		99	99
41					10	20	10	10	10	100	10	20		90	95
42	<10%	10-20%	<10%	<10%					<10%	>80%	<10%	<10%	95		90
45					1	1	1	1	1	8	1	1		80	70
51					0	1	0	4	0	8	0	8		95	90
54					<10%	0.1	<10%	0.3	0.1	>90%	<10%	0.2		99	95
58					<5%	Equivocal	<5%	80%	<5%	100%	<5%	90%		95	90
117	2	0	1	1									70		
136					1	1	1	1						98	
149	2-4	4-6	-	-									81		
205	+++	++++	-	-					+++	++++	-	-	90	90	90
212													99	99	99
311					1		1	1	1	8	1	1		100	100
315					1		1	1	1	8	1	1	0.9	0.9	0.9

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A01/2017 WB

DESPATCHED ON 31ST JANUARY 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A11, A24; B7, B18; Cw7, Cw-; DR11, DR15; DQ6, DQ7

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	10	9	10	10	19	16	19	19	21	21	21	21				
Positive	2	9	0	4	0	6	0	5	1	21	0	9				
Negative	8	0	10	6	19	10	19	14	20	0	21	12				
NT/Equivocal	0	1	0	0	0	3	0	0	0	0	0	0				
% Positive	20.0%	100.0%	0.0%	40.0%	0.0%	37.5%	0.0%	26.3%	4.8%	100.0%	0.0%	42.9%				
% Negative	80.0%	0.0%	100.0%	60.0%	100.0%	62.5%	100.0%	73.7%	95.2%	0.0%	100.0%	57.1%				
Consensus	Negative	Positive	Negative	Not Assessed	Negative	Not Assessed	Negative	Not Assessed	Negative	Positive	Negative	Not Assessed				
HLA Antibody Specificity (Defined By CDC)	A3	A10, B16, DQ1	B44, Cw5, DR4	?Bw6	A3	A10, B16, DQ1	B44, Cw5, DR4	?Bw6	A3	A10, B16, DQ1	B44, Cw5, DR4	?Bw6				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	
11	YES	YES	YES	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	Negative	Positive	
12	YES	YES	YES	Negative	Equivocal	Negative	Negative	Negative	Equivocal	Negative	Negative	Negative	Positive	Negative	Negative	
14		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	
15		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
20	YES		YES	Negative	Positive	Negative	Negative					Negative	Positive	Negative	Negative	
24		YES	YES					Negative	Negative	Negative	Positive	Negative	Positive	Negative	Positive	
25		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
28		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
34		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	
35	YES	YES		Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive					
38	YES	YES	YES	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
39		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
41		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive	
42	YES		YES	Negative	Positive	Negative	Negative					Negative	Positive	Negative	Positive	
45		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
51		YES	YES					Negative	Equivocal	Negative	Positive	Negative	Positive	Negative	Positive	
58		YES	YES					Negative	Equivocal	Negative	Positive	Negative	Positive	Negative	Positive	
149	YES			Positive	Positive	Negative	Negative					Positive	Positive	Negative	Negative	
205	YES		YES	Positive	Positive	Negative	Negative					Positive	Positive	Negative	Negative	
212	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
311		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
315		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A01/2017 WB

DESPATCHED ON 31ST JANUARY 2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	4	0	2	0	2	0	0	0	8	0	2	95	95	90
11	-	2	-	2	-	-	-	6	-	8	-	6	95	95	95
12	-	Equivocal	-	-	-	Equivocal	-	-	-	100%	-	-	90	90	90
14					0	0	0	0	0	8	0	6		90	90
15					0	0	0	0	0	8	0	0		95	95
20	10%	30%	10%	10%					10%	90%	10%	10%	90		90
24					10%	20%	10%	40%	20%	100%	20%	70%		90	80
25					1	1	1	1	1	8	1	1		85	80
28					1	1	1	1	1	8	1	1		99	90
34					1	1	1	1	1	8	1	2		99	90
35	1	2	1	4	1	6	1	8					70	60	
38	1	2	1	2	1	4	1	1	1	8	1	1	85	85	85
39					-	-	-	-	-	8	-	-		99	99
41					10	30	10	10	10	100	10	30		90	95
42	<10%	10-20%	<10%	<10%					<10%	>80%	<10%	10-20%	95		90
45					1	1	1	1	1	8	1	1		80	70
51					0	1	0	4	0	8	0	6		95	90
58					<5%	Equivocal	<5%	80%	<5%	100%	<5%	90%		95	90
149	2-4	4-6	-	-									81		
205	+++	++++	-	-					+++	++++	-	-	90	90	90
212													99	99	99
311					1	2	1	1	1	8	1	1		100	100
315					1	1	1	1	1	8	1	1	0.9	0.9	0.9